Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL Meeting Abstract
| Authors: | Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J. |
| Abstract Title: | Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394446805063 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.58.58 |
| Notes: | Meeting Abstract: 58 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work